Related references
Note: Only part of the references are listed.Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
Tian Zhang et al.
BIOMARKER RESEARCH (2021)
Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates
MaryBeth B. Culp et al.
EUROPEAN UROLOGY (2020)
Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer
Wojciech A. Cieslikowski et al.
CANCERS (2020)
Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations
Thomas Van den Broeck et al.
EUROPEAN UROLOGY FOCUS (2020)
Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5
Ziqian Li et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls
Sara Sheikhbahaei et al.
SEMINARS IN NUCLEAR MEDICINE (2019)
In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy
Shukun Chen et al.
CANCERS (2019)
Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone
Hernan Roca et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Genetics and biology of prostate cancer
Guocan Wang et al.
GENES & DEVELOPMENT (2018)
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging
Sara Sheikhbahaei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2017)
Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells
Brian M. Olson et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
Wolfgang Lilleby et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JAMA ONCOLOGY (2016)
Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients
Andra Kuskel et al.
SCIENTIFIC REPORTS (2016)
Using circulating tumor cells to inform on prostate cancer biology and clinical utility
Jing Li et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2015)
Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Enhancing chemotherapy efficacy by reprogramming the senescence-associated secretory phenotype of prostate tumors A way to reactivate the antitumor immunity
Alberto Toso et al.
ONCOIMMUNOLOGY (2015)
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial
Amir Goldkorn et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer
Goran Benko et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
EpCAM and its potential role in tumor-initiating cells
Sannia Imrich et al.
CELL ADHESION & MIGRATION (2012)
Pro-senescence therapy for cancer treatment
Caterina Nardella et al.
NATURE REVIEWS CANCER (2011)
Potential role of immunosenescence in cancer development
Tamas Fulop et al.
AGING, CANCER, AND AGE-RELATED DISEASES: COMMON MECHANISM? (2010)
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters
Kathleen Ebelt et al.
EUROPEAN JOURNAL OF CANCER (2009)
Parallel progression of primary tumours and metastases
Christoph A. Klein
NATURE REVIEWS CANCER (2009)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer
Daniel C. Danila et al.
CLINICAL CANCER RESEARCH (2007)
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
CG Drake et al.
CANCER CELL (2005)
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
M Mercader et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
